Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 10/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6087619 | 0.78 | TSHR (0.54) | IMPDH2MAPTLMNATSHRMAPK1 | |
| SCHEMBL1777994 | 0.75 | IMPDH2 (0.56) | IMPDH2MAPTHTTSLC6A4GSK3B | |
| SCHEMBL6088495 | 0.73 | AR (0.45) | IMPDH2ARSLC6A4IMPDH1 | |
| SCHEMBL7859196 | 0.72 | CA2 (0.52) | ARMAPTLMNATSHRMAPK1 | |
| SCHEMBL30832957 | 0.72 | CA2 (0.52) | ARMAPTLMNATSHRMAPK1 | |
| SCHEMBL6090667 | 0.71 | AR (0.46) | IMPDH2AR | |
| SCHEMBL6088237 | 0.71 | SRC (0.47) | IMPDH2ARSLC6A4SRC | |
| SCHEMBL31687136 | 0.70 | TUBB1 (0.48) | SRC | |
| SCHEMBL7293153 | 0.70 | IMPDH2 (0.61) | IMPDH2LMNAHTTSLC6A4MAOA | |
| SCHEMBL31687153 | 0.69 | CYP1A1 (0.54) | IMPDH2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125906-B2 | Indole derivatives having anti-angiogenetic activity | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | claimed |
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | US | claimed |
| US-7125906-B2 | Indole derivatives having anti-angiogenetic activity | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | US | disclosed |
| EP-1515716-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | Astrazeneca AB (SE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003082271-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | FLT1, FLT4, VEGFA | IMPDH2 3719/4885AR 3468/4885MAPT 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.